文献速递药物相互作用

艾乐替尼CYP介导药物相互作用风险的模型评估:PBPK建模支持临床开发

Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
PubMed 文献 · Clin Pharmacol Ther · 2017-12-27

艾乐替尼及其活性代谢物M4在体外显示经CYP3A4和CYP2C8的DDI潜力。本研究采用生理药代动力学(PBPK)建模结合有限临床试验的策略评估DDI风险,结果表明艾乐替尼经CYP3A4的受害者DDI风险低,临床相关暴露下对CYP2C8和CYP3A4酶调节作用可忽略,支持无需因CYP介导的DDI调整剂量。

要点

  • 艾乐替尼经CYP3A4的受害者DDI风险低,无需剂量调整。
  • 临床相关暴露下对CYP2C8和CYP3A4酶调节作用可忽略。
  • PBPK建模结合有限临床试验可有效外推DDI风险。

核心结论

  • 艾乐替尼可处方时无需因CYP介导的DDI风险进行剂量调整。

研究设计与样本

  • 采用PBPK建模与有限临床试验相结合的策略,以评估DDI风险并确保外推能力。

主要发现

  • 通过fmCYP3A4和FG的二维分析,PBPK建模提供了艾乐替尼经CYP3A4的受害者DDI风险低的机制见解。
  • 在临床相关暴露下,艾乐替尼对CYP2C8和CYP3A4的酶调节作用可忽略。

临床怎么用

  • 临床处方艾乐替尼时,无需因CYP介导的DDI风险调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alectinib is a selective anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro. Clinical relevance of the DDI risk was investigated as part of a rapid development program to fulfill the breakthrough therapy designation. Therefore, a strategy with a combination of physiologically based pharmacokinetic (PBPK) modeling and limited clinical trials focused on generating informative data for modeling was made to ensure extrapolation ability of DDI risk. The PBPK modeling has provided mechanistic insight into the low victim DDI risk of alectinib through CYP3A4 by a novel two-dimensional analysis for fmCYP3A4 and FG , and demonstrated negligible CYPs 2C8 and 3A4 enzyme-modulating effects at clinically relevant exposure. This work supports that alectinib can be prescribed without dose adjustment for CYP-mediated DDI liabilities.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cleary Y, Gertz M, Morcos PN, et al. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development. Clin Pharmacol Ther. 2017. PMID: 29226313. doi:10.1002/cpt.956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。